{
    "clinical_study": {
        "@rank": "48677", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo oral solution is presented as an oily solution containing excipients, sesame oil, ethanol, sucralose and strawberry flavouring.\nDose: 5 mL Placebo oral solution to be taken twice daily for 6 weeks.\nThe total dose administered within any 24-hour interval will be 10 mL of oral solution."
            }, 
            {
                "arm_group_label": "GWP42003", 
                "arm_group_type": "Active Comparator", 
                "description": "GWP42003 oral solution is presented as an oily solution containing 100 mg/mL of cannabidiol (CBD) dissolved in excipients, sesame oil, ethanol, sucralose and strawberry flavouring.\nDose: 5 mL GWP42003 (500 mg CBD) oral solution to be taken twice daily for 6 weeks.\nThe total dose administered within any 24-hour interval will be 10 mL of oral solution (1 g CBD)."
            }
        ], 
        "brief_summary": {
            "textblock": "A study to compare the change in symptom severity in patients with schizophrenia or related\n      psychotic disorder when treated with GWP42003 or placebo, added to existing anti-psychotic\n      therapy over a period of six weeks.  Secondary objectives are to evaluate the effect of\n      GWP42003 on quality of life and cognition and to assess the safety and tolerability of\n      GWP42003."
        }, 
        "brief_title": "A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Schizophrenia", 
            "Schizophrenia-related Psychotic Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Psychotic Disorders", 
                "Mental Disorders", 
                "Schizophrenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This eight-week (six week treatment period and two week follow-up), multi-centre,\n      double-blind, randomised, placebo-controlled, parallel group study aims to determine the\n      efficacy, safety and tolerability of GWP42003 in patients with schizophrenia or a related\n      psychotic disorder.\n\n      Eligible subjects will enter the study at a Screening and Randomisation Visit (Visit 1, Day\n      1), where the following information will be obtained for each participant:\n\n        1. Informed consent\n\n        2. Demographics\n\n        3. Medical history\n\n        4. Physical examination\n\n        5. Electrocardiogram (ECG)\n\n        6. Vital signs\n\n        7. Pregnancy test (if appropriate)\n\n        8. Safety blood test (biochemistry and haematology)\n\n        9. Efficacy blood test (plasma cannabinoid levels, serum High Density Lipoprotein\n           [HDL]-Cholesterol [C] levels, serum prolactin levels and markers of inflammation)\n\n       10. Urinalysis (including drugs of abuse screen)\n\n       11. Concomitant medications (current and recent)\n\n       12. Assessment of schizophrenia or related psychotic disorder symptom severity (positive,\n           negative and general)\n\n       13. Severity of mental illness\n\n       14. Assessment of functional ability (social, occupational and psychological)\n\n       15. Severity of Parkinsonian symptomatology (rigidity)\n\n       16. Assessment of cognition\n\n       17. Current substance abuse status (if applicable)\n\n       18. Current dependence disorders and frequency of abuse (if applicable).\n\n       19. Body weight\n\n       20. Body Mass index (BMI)\n\n       21. Waist circumference\n\n      Once all inclusion and exclusion criteria have been reviewed, participants will be\n      randomised to receive either GWP42003 or placebo alongside their prescribed anti-psychotic\n      medications and begin treatment at Visit 1 as instructed.\n\n      A second (Visit 2, Day 8) and third (Visit 3, Day 22) visit will take place mid-treatment,\n      where the following assessments will be performed:\n\n        1. Assessment of schizophrenia or related psychotic disorder symptom severity (positive,\n           negative and general)\n\n        2. Severity of mental illness and level of change since baseline\n\n        3. Assessment of functional ability (social, occupational and psychological)\n\n        4. Severity of Parkinsonian symptomatology (rigidity)\n\n        5. Assessment of cognition\n\n        6. Review of concomitant medications\n\n        7. Review of medication compliance\n\n        8. Participant's global impression of change since baseline\n\n        9. Carer's global impression of change since baseline (if applicable)\n\n       10. Safety assessments (Adverse Event(s) (AE))\n\n       11. Body weight\n\n       12. BMI\n\n       13. Waist circumference\n\n      In addition, a safety blood test and efficacy blood test will also be performed during the\n      third visit (Visit 3, Day 22).\n\n      A further visit will take place at the end of treatment (Visit 4, Day 43), where the\n      following assessments will be performed:\n\n        1. Assessment of schizophrenia or related psychotic disorder symptom severity (positive,\n           negative and general)\n\n        2. Severity of mental illness and level of change since baseline\n\n        3. Assessment of functional ability (social, occupational and psychological)\n\n        4. Severity of Parkinsonian symptomatology (rigidity)\n\n        5. Assessment of cognition\n\n        6. Physical examination\n\n        7. Review of concomitant medications\n\n        8. Review of medication compliance\n\n        9. Participant's global impression of change since baseline\n\n       10. Caregiver's global impression of change since baseline (if applicable)\n\n       11. Safety assessments (AEs)\n\n       12. ECG\n\n       13. Safety blood test\n\n       14. Efficacy blood test\n\n       15. Urinalysis (including drugs of abuse screen)\n\n       16. Pregnancy test (if appropriate)\n\n       17. Physical examination\n\n       18. Vital signs\n\n       19. Body weight\n\n       20. BMI\n\n       21. Waist circumference\n\n       22. Review of dependence disorders (if applicable)\n\n      There will be a safety follow-up telephone following the end of treatment (Visit 5, Day 57),\n      which will involve a review of any new or ongoing AEs and changes to concomitant\n      medications."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (all must be fulfilled):\n\n          -  Patient is willing and able to give written informed consent for participation in the\n             study and does not require involuntary treatment.\n\n          -  Patient is male or female aged 18 to 65 years.\n\n          -  Patient is able (in the investigator's opinion) and willing to comply with all study\n             requirements.\n\n          -  Patient is diagnosed with schizophrenia or a related psychotic disorder (such as\n             schizoaffective or schizophreniform disorder) as defined by the Diagnostic and\n             Statistical Manual of Mental Disorders Version 4.\n\n          -  Patient must have been treated for a minimum of four-weeks and be on a stable dose of\n             their current anti-psychotic (AP) medication.\n\n          -  Patient must have shown the capacity to respond at least partially to first line AP\n             medication in the opinion of the investigator.\n\n          -  Patient must be able to remain stable on their dose of AP and concomitant medications\n             for the duration of the study, in the opinion of the investigator.\n\n          -  Patient is willing for his or her name to be notified to the responsible authorities\n             for participation in this study, as applicable in individual countries.\n\n          -  Patient is willing to allow his or her primary care practitioner and consultant, if\n             appropriate, to be notified of participation in the study.\n\n        Exclusion Criteria (any of the following):\n\n          -  Any known or suspected hypersensitivity to cannabinoids or any of the excipients of\n             the Investigational Medicinal Product.\n\n          -  Patient has a Positive and Negative Symptom Scale total score of < 60 at Visit 1.\n\n          -  Patient presents with a current clinical picture and/or history that is consistent\n             with:\n\n             i. delirium or dementia ii. acute drug induced psychosis iii. bipolar disorder\n\n          -  Patient is taking more the one AP medication during the study.\n\n          -  Female patients of child bearing potential and male patients whose partner is of\n             child bearing potential, unless willing to ensure that they or their partner use\n             effective contraception, for example, oral contraception, double barrier,\n             intra-uterine device, during the study and for three months thereafter (however a\n             male condom should not be used in conjunction with a female condom).\n\n          -  Female patient who is pregnant, lactating or planning pregnancy during the course of\n             the study and for three months thereafter.\n\n          -  Patients who have received an Investigational Medicinal Product within 30 days prior\n             to the screening visit.\n\n          -  Any other significant disease or disorder which, in the opinion of the investigator,\n             may either put the patient at risk because of participation in the study, may\n             influence the result of the study, or the patient's ability to participate in the\n             study.\n\n          -  Following a physical examination, the patient has any abnormalities that, in the\n             opinion of the investigator would prevent the patient from safe participation in the\n             study.\n\n          -  Unwilling to abstain from donation of blood during the study.\n\n          -  Travel outside the country of residence planned during the study.\n\n          -  Patient previously randomised into this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006628", 
            "org_study_id": "GWAP1241", 
            "secondary_id": "2013-000212-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Patients will self-administer their allocated randomised treatment twice daily (in the morning and in the evening) for six weeks using the dosing spoons provided with each bottle. Study medication will be swallowed and may be taken with other concomitant medications, as directed by the investigator.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo control"
            }, 
            {
                "arm_group_label": "GWP42003", 
                "description": "Patients will self-administer their allocated randomised treatment twice daily (in the morning and in the evening) for six weeks using the dosing spoons provided with each bottle. Study medication will be swallowed and may be taken with other concomitant medications, as directed by the investigator.", 
                "intervention_name": "GWP42003", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cannabidiol", 
                    "Epidiolex"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "GWP42003", 
            "Cannabinoids", 
            "Schizophrenia"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Ward Lawrence"
                }, 
                "facility": {
                    "address": {
                        "city": "Chertsey", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Investigator 2"
                }, 
                "investigator": {
                    "last_name": "Ward Lawrence", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Victoria Gordon"
                }, 
                "facility": {
                    "address": {
                        "city": "Coventry", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Investigator 1"
                }, 
                "investigator": {
                    "last_name": "Bettahalasoor Somashekar", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Investigator 3"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in First Line Treatment of Schizophrenia or Related Psychotic Disorder", 
        "overall_contact": {
            "email": "kbrooke@gwpharm.com", 
            "last_name": "Keeley Brooke, BSc (hons) MSc", 
            "phone": "+44 (0)1223 266797"
        }, 
        "overall_official": {
            "affiliation": "Institute of Psychiatry, King's College London, De Crespigny Park, London, SE5 8AF, UK", 
            "last_name": "Philip McGuire, MD PhD FRCPsych FMedSci", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The PANSS is a medical scale completed by a trained rater at site and is used for measuring symptom severity of patients with schizophrenia or related psychotic disorder. It is a 30 item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. A PANSS total score is derived from the sum of the 30 items and the PANSS items are also grouped into three subscales: Positive ('P'), Negative ('N'), and General ('G'). Individual items are rated on a seven point scale, where 1 = absent and 7 = extreme. A decrease in total score indicates an improvement in condition.", 
            "measure": "Change from baseline to the end of treatment in Positive and Negative Syndrome Scale (PANSS) total score.", 
            "safety_issue": "No", 
            "time_frame": "0-43 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006628"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The PANSS is a medical scale completed by a trained rater at site and is used for measuring symptom severity of patients with schizophrenia or related psychotic disorder. It is a 30 item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. A PANSS total score is derived from the sum of the 30 items and the PANSS items are also grouped into three subscales: Positive ('P'), Negative ('N'), and General ('G'). Individual items are rated on a seven point scale, where 1 = absent and 7 = extreme. Changes in the Positive subscale of the PANSS are presented. A decrease in score indicates an improvement in condition.", 
                "measure": "Change from baseline to the end of treatment in Positive and Negative Syndrome Scale (PANSS) 'P' score.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "The PANSS is a medical scale completed by a trained rater at site and is used for measuring symptom severity of patients with schizophrenia or related psychotic disorder. It is a 30 item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. A PANSS total score is derived from the sum of the 30 items and the PANSS items are also grouped into three subscales: Positive ('P'), Negative ('N'), and General ('G'). Individual items are rated on a seven point scale, where 1 = absent and 7 = extreme. Changes in the Negative subscale of the PANSS are presented. A decrease in score indicates an improvement in condition.", 
                "measure": "Change from baseline to the end of treatment in Positive and Negative Syndrome Scale (PANSS) 'N' score.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "The PANSS is a medical scale completed by a trained rater at site and is used for measuring symptom severity of patients with schizophrenia or related psychotic disorder. It is a 30 item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. A PANSS total score is derived from the sum of the 30 items and the PANSS items are also grouped into three subscales: Positive ('P'), Negative ('N'), and General ('G'). Individual items are rated on a seven point scale, where 1 = absent and 7 = extreme. Changes in the General subscale of the PANSS are presented. A decrease in score indicates an improvement in condition.", 
                "measure": "Change from baseline to the end of treatment in Positive and Negative Syndrome Scale (PANSS) 'G' score.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "SANS assesses five symptom complexes to obtain clinical ratings of negative symptoms in patients with schizophrenia or related psychotic disorder. They are: affective blunting; alogia (impoverished thinking); avolition/apathy; anhedonia/asociality; and disturbance of attention. Assessments are conducted on a six-point scale (0 = not at all to 5 = severe). A decrease in score indicates an improvement in condition.", 
                "measure": "Change from baseline to the end of treatment in Scale for the Assessment of Negative Symptoms (SANS) total score.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "The CGI-S is a seven point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient will be assessed on severity of mental illness at the time of rating. The markers are:\nNot at all ill, Borderline mentally ill, Mildly ill, Moderately ill, Markedly ill, Severely ill, Extremely ill.\nThe number of patients for each of the markers at the final study visit is presented.", 
                "measure": "Change in the severity of mental illness at the end of treatment relative to baseline using the Clinical Global Impressions - Severity Scale (CGI-S).", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "The CGI-I is a seven point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The markers are:\nVery much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse.\nThe number of patients for each of the markers at the final study visit is presented.", 
                "measure": "Improvement in mental illness at the end of treatment relative to baseline using the Clinical Global Impressions - Improvement Scale (CGI-I).", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "The GAF is a numeric scale (0 through 100) used by mental health clinicians and physicians alike to subjectively rate the social, occupational, and psychological functioning of adults. The patient will be assigned a code related to the group that best describes the patient's functioning. Patients assigned the code 91-100 are deemed to have:\n\"Superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many positive qualities. No symptoms.\"\nPatients assigned the code 1-10 are deemed in:\n\"Persistent danger of severely hurting self or others (e.g., recurrent violence) OR persistent inability to maintain minimal personal hygiene OR serious suicidal act with clear expectation of death.\"\nA decrease in score indicates an improvement in condition.", 
                "measure": "Change from baseline to the end of treatment in Global Assessment of Functioning (GAF) score.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "The SAS is a 10-item instrument used to evaluate the presence and severity of Parkinsonian symptomatology. The ten items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a 0-4 scale, where 0 is indicative of 'normal' and 4 being the most severe. Definitions are given for each anchor point within each item and a total score is obtained by summing over the 10 items. The 10 items that are scored are: Gait; Arm Dropping; Shoulder Shaking; Elbow Rigidity; Wrist Rigidity or Fixation of Position; Leg Pendulousness; Head Dropping; Glabella Tap; Tremor and Salivation. A decrease in score indicates an improvement in condition.", 
                "measure": "Change from baseline to the end of treatment in Simpson-Angus Scale (SAS) total score.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "The BACS is an instrument used to assess the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia or related psychotic disorder. The BACS consists of six domains: verbal memory; working memory; motor speed; verbal fluency; attention and speed information processing and executive functions. A score is obtained for each domain and a composite summary score is also calculated as the average of the scores from the six domains. An increase in score indicates an improvement in cognition.", 
                "measure": "Change from baseline to the end of treatment in Brief Assessment of Cognition in Schizophrenia (BACS) average score.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "If applicable, carers will be asked the following three questions to be rated on a seven-point scale:\n\"How has the participant's general functional ability changed since Visit 1?\"\n\"How has the participant's quantity of sleep changed since Visit 1?\"\n\"How has the participant's quality of sleep changed since Visit 1?\"\nThe markers are: Very much worse, Much worse, Slightly worse, No change, Slightly improved, Much improved, Very much improved.\nThe number of patients for each of the markers at the final study visit is presented.", 
                "measure": "Carer Global Impression of Change (CGIC) in the patient's general functional ability and sleep at the end of treatment relative to baseline.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Patients will be asked the following three questions to be rated on a seven-point scale:\n\"How has your general functional ability changed since Visit 1?\"\n\"How has your quantity of sleep changed since Visit 1?\"\n\"How has your quality of sleep changed since Visit 1?\"\nThe markers are: Very much worse, Much worse, Slightly worse, No change, Slightly improved, Much improved, Very much improved.\nThe number of patients for each of the markers at the final study visit is presented.", 
                "measure": "Participant Global Impression of Change (PGIC) in the patient's general functional ability and sleep at the end of treatment relative to baseline.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "If applicable, patients will be asked if their dependence disorder has changed since baseline.\nThe markers are: Remained the same, Increased, Decreased, Both (if the participant is using more than one substance, there may be both an increase and a decrease), Don't know.\nThe number of patients for each of the markers at the final study visit is presented.", 
                "measure": "Change in dependence disorder at the end of treatment relative to baseline.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Body weight (kg) will be measured at baseline and at the end of treatment.", 
                "measure": "Change from baseline to the end of treatment in mean body weight.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Waist circumference will be measured at baseline and at the end of treatment.", 
                "measure": "Change from baseline to the end of treatment in mean waist circumference.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Individual subject's BMIs will be calculated at baseline and at the end of treatment by dividing mass (kg) by height (m2).", 
                "measure": "Change from baseline to the end of treatment in mean Body Mass Index (BMI).", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum HDL-C levels will be measured in blood samples taken at baseline and at the end of treatment.", 
                "measure": "Change from baseline to the end of treatment in mean serum High Density Lipoprotein (HDL)-Cholesterol (C) levels.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum total bilirubin will be measured in blood samples taken at baseline and at the end of treatment as a measure of liver function.", 
                "measure": "Change from baseline to the end of treatment in mean serum bilirubin.", 
                "safety_issue": "Yes", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum alkaline phosphatase levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of liver function.", 
                "measure": "Change from baseline to the end of treatment in mean serum alkaline phosphatase levels.", 
                "safety_issue": "Yes", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum AST levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of liver function.", 
                "measure": "Change from baseline to the end of treatment in mean serum Aspartate Aminotransferase (AST) levels.", 
                "safety_issue": "Yes", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum ALT levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of liver function.", 
                "measure": "Change from baseline to the end of treatment in mean serum Alanine Aminotransferase (ALT) levels.", 
                "safety_issue": "Yes", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum Gamma-Glutamyl Transferase levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of liver function.", 
                "measure": "Change from baseline to the end of treatment in mean serum Gamma-Glutamyl Transferase levels.", 
                "safety_issue": "Yes", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum Prolactin levels will be measured in blood samples taken at baseline and at the end of treatment.", 
                "measure": "Change from baseline to the end of treatment in mean serum Prolactin levels.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum CRP levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of inflammation.", 
                "measure": "Change from baseline to the end of treatment in mean serum C-Reactive Protein (CRP) levels.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum IL-2 levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of inflammation.", 
                "measure": "Change from baseline to the end of treatment in mean serum Interleukin-2 (IL-2) levels.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum IL-6 levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of inflammation.", 
                "measure": "Change from baseline to the end of treatment in mean serum Interleukin-6 (IL-6) levels.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Serum Interferon gamma levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of inflammation.", 
                "measure": "Change from baseline to the end of treatment in mean serum Interferon gamma levels.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "Plasma cannabinoid levels will be measured in blood samples taken at baseline and at the end of treatment as a measure of treatment compliance and dosage.", 
                "measure": "Change from baseline to the end of treatment in mean plasma cannabinoid levels.", 
                "safety_issue": "No", 
                "time_frame": "0-43 days"
            }, 
            {
                "description": "The number of subjects who experience an AE during the course of the study will be presented. All reported AEs will be classified by system organ class and preferred term using the current Medical Dictionary for Regulatory Activities  dictionary.", 
                "measure": "Incidence of Adverse Events (AEs) as a measure of patient safety.", 
                "safety_issue": "Yes", 
                "time_frame": "0-57 days"
            }
        ], 
        "source": "GW Pharmaceuticals Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GW Pharmaceuticals Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}